The drug manufactured by Pharmasyntez-Nord and used to treat prostate cancer became the first Russian drug to receive marketing authorization in the Dominican Republic.

Demand for the drug in the vast market of Latin America may be explained by high quality of the product, which is manufactured using state-of-the-art equipment under strict control in accordance with the requirements of Good Manufacturing Practice of the Russian Federation at the facilities of Pharmasyntez-Nord in St. Petersburg. Therefore, it is in demand in the vast market of Latin America.

At the moment Pharmasyntez is the first and only Russian pharmaceutical company preparing to export drugs to the Dominican Republic.